131 related articles for article (PubMed ID: 32450073)
21. The wrath of RAFs: rogue behavior of B-RAF kinase inhibitors.
Kaplan FM; Mastrangelo MJ; Aplin AE
J Invest Dermatol; 2010 Nov; 130(11):2669-71. PubMed ID: 20574441
[No Abstract] [Full Text] [Related]
22. KIT Suppresses BRAF
Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
[TBL] [Abstract][Full Text] [Related]
23. Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays.
Fisher KE; Cohen C; Siddiqui MT; Palma JF; Lipford EH; Longshore JW
Hum Pathol; 2014 Nov; 45(11):2281-93. PubMed ID: 25228337
[TBL] [Abstract][Full Text] [Related]
24. Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma.
Cohen JV; Sullivan RJ
Clin Cancer Res; 2019 Oct; 25(19):5735-5742. PubMed ID: 30992297
[TBL] [Abstract][Full Text] [Related]
25. BRAF V600E mutational load as a prognosis biomarker in malignant melanoma.
Sevilla A; Morales MC; Ezkurra PA; Rasero J; Velasco V; Cancho-Galan G; Sánchez-Diez A; Mujika K; Penas C; Smith I; Asumendi A; Cortés JM; Boyano MD; Alonso S
PLoS One; 2020; 15(3):e0230136. PubMed ID: 32168325
[TBL] [Abstract][Full Text] [Related]
26. Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and
García-Silva S; Benito-Martín A; Sánchez-Redondo S; Hernández-Barranco A; Ximénez-Embún P; Nogués L; Mazariegos MS; Brinkmann K; Amor López A; Meyer L; Rodríguez C; García-Martín C; Boskovic J; Letón R; Montero C; Robledo M; Santambrogio L; Sue Brady M; Szumera-Ciećkiewicz A; Kalinowska I; Skog J; Noerholm M; Muñoz J; Ortiz-Romero PL; Ruano Y; Rodríguez-Peralto JL; Rutkowski P; Peinado H
J Exp Med; 2019 May; 216(5):1061-1070. PubMed ID: 30975894
[TBL] [Abstract][Full Text] [Related]
27. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival.
Cartlidge RA; Thomas GR; Cagnol S; Jong KA; Molton SA; Finch AJ; McMahon M
Pigment Cell Melanoma Res; 2008 Oct; 21(5):534-44. PubMed ID: 18715233
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.
Anwar MA; Murad F; Dawson E; Abd Elmageed ZY; Tsumagari K; Kandil E
J Surg Res; 2016 Jun; 203(2):407-15. PubMed ID: 27363650
[TBL] [Abstract][Full Text] [Related]
29. Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma.
Koomen JM; Smalley KS
Oncotarget; 2011 Apr; 2(4):329-35. PubMed ID: 21505227
[TBL] [Abstract][Full Text] [Related]
30. Progression of NRAS and BRAF mutations in cutaneous melanoma.
Rosso R; Romagosa Y; Kirsner RS
J Invest Dermatol; 2009 Jun; 129(6):1318. PubMed ID: 19434085
[No Abstract] [Full Text] [Related]
31. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
Yeh AH; Bohula EA; Macaulay VM
Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
[TBL] [Abstract][Full Text] [Related]
32. BRAF Mutation Heterogeneity in Melanoma Lesions.
Sakaizawa K; Ashida A; Kiniwa Y; Okuyama R
Acta Derm Venereol; 2020 Jan; 100(1):adv00045. PubMed ID: 31821518
[No Abstract] [Full Text] [Related]
33. On oncogenic BRAF, melanomagenesis and organ transplant recipients--"the more we know, the less we understand".
Mahalingam M
Eur J Dermatol; 2010; 20(2):143. PubMed ID: 20007066
[No Abstract] [Full Text] [Related]
34. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma.
Siroy AE; Aung PP; Torres-Cabala CA; Tetzlaff MT; Nagarajan P; Milton DR; Curry JL; Ivan D; Prieto VG
Hum Pathol; 2017 Jan; 59():48-54. PubMed ID: 27666765
[TBL] [Abstract][Full Text] [Related]
35. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
[TBL] [Abstract][Full Text] [Related]
36. BRAF mutations in melanocytic lesions and papillary thyroid carcinoma samples identified using melting curve analysis of polymerase chain reaction products.
Hay R; MacRae E; Barber D; Khalil M; Demetrick DJ
Arch Pathol Lab Med; 2007 Sep; 131(9):1361-7. PubMed ID: 17824790
[TBL] [Abstract][Full Text] [Related]
37. Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation.
Yazdi AS; Ghoreschi K; Sander CA; Röcken M
Eur J Dermatol; 2010; 20(5):575-9. PubMed ID: 20605766
[TBL] [Abstract][Full Text] [Related]
38. BRAF V600E mutation-specific antibody: A review.
Ritterhouse LL; Barletta JA
Semin Diagn Pathol; 2015 Sep; 32(5):400-8. PubMed ID: 25744437
[TBL] [Abstract][Full Text] [Related]
39. Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?
Sigalotti L; Fratta E; Parisi G; Coral S; Maio M
Br J Cancer; 2011 Jul; 105(2):327-8. PubMed ID: 21694724
[No Abstract] [Full Text] [Related]
40. Oncogenic BRAF-Mediated Melanoma Cell Invasion.
Lu H; Liu S; Zhang G; Kwong LN; Zhu Y; Miller JP; Hu Y; Zhong W; Zeng J; Wu L; Krepler C; Sproesser K; Xiao M; Xu W; Karakousis GC; Schuchter LM; Field J; Zhang PJ; Herlyn M; Xu X; Guo W
Cell Rep; 2016 May; 15(9):2012-24. PubMed ID: 27210749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
